Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression
Childhood adversities have been associated with onset and worse clinical presentations of depression. Epigenetic changes may reflect childhood adversities, while their effects on clinical characteristics of depression are unknown. This study aimed to investigate whether epigenetic changes were assoc...
Gespeichert in:
| Veröffentlicht in: | Progress in neuro-psychopharmacology & biological psychiatry 2013-07, Vol.44, p.23-28 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 28 |
|---|---|
| container_issue | |
| container_start_page | 23 |
| container_title | Progress in neuro-psychopharmacology & biological psychiatry |
| container_volume | 44 |
| creator | Kang, Hee-Ju Kim, Jae-Min Stewart, Robert Kim, Seon-Young Bae, Kyung-Yeol Kim, Sung-Wan Shin, Il-Seon Shin, Myung-Geun Yoon, Jin-Sang |
| description | Childhood adversities have been associated with onset and worse clinical presentations of depression. Epigenetic changes may reflect childhood adversities, while their effects on clinical characteristics of depression are unknown. This study aimed to investigate whether epigenetic changes were associated with childhood adversities, pretreatment characteristics, and treatment outcomes in depressive patients. In 108 patients with major depressive disorders, the methylation status in the promoter of gene encoding serotonin transporter (SLC6A4) was measured. Childhood adversities, socio-demographic and clinical characteristics including assessment scales for depression (Hamilton Depression Rating Scale, HAMD), anxiety (Hamilton Anxiety Rating Scale, HAMA), functioning (Social and Occupational Functioning Assessment Scale, SOFAS), disability (World Health Organization Disability Assessment Schedule-12, WHODAS-12), and quality of life (World Health Organization Quality of Life-Abbreviated form, WHOQOL-BREF) were evaluated at baseline. After a 12-week treatment with antidepressants, the assessment scales were reevaluated. To avoid type I error by multiple comparisons, Bonferroni corrections were applied. Higher SLC6A4 promoter methylation status was significantly associated with childhood adversities, worse clinical presentation (family history of depression, higher perceived stress, and more severe psychopathology assessed by SOFAS, WHODAS-12, and WHOQOL-BREF), but was not associated with treatment outcomes after considering multiple comparisons. SLC6A4 methylation status could be a proxy marker for childhood adversities and a clinical biomarker for certain presentations of depression.
► SLC6A4 methylation was associated with childhood adversity in depressive patients. ► SLC6A4 methylation was associated with more severe depression at presentation. ► Associations of SLC6A4 methylation with treatment outcomes are yet to be determined. ► SLC6A4 methylation could be a biomarker for certain presentations of depression. |
| doi_str_mv | 10.1016/j.pnpbp.2013.01.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1372055288</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0278584613000080</els_id><sourcerecordid>1372055288</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-954108fb1315d9af9a09f608894da20e557e673851f598e9e1bc5850351bcc633</originalsourceid><addsrcrecordid>eNqNkU2LFDEQhoMo7rj6CwTJRfCw01aSTnf64GEYXBUGPKjnkE5XMxn6y1RmZf69GWfUm1iXKoqnPnhfxl4KKASI6u2hWKalXQoJQhUgCoDqEVsJU5t1KUX1mK1A5lqbsrphz4gOAJkE9ZTdSHWOulqxdkM0--BSmCc-9_zLblttSj5i2p-GS_dHSHuOLg4n7roHjBTS6Y77vYvOJ4yBUvDE3dTx-Zj8PCLxMPEOl4hEecFz9qR3A-GLa75l3-7ff91-XO8-f_i03ezWvpQyrRtdCjB9K5TQXeP6xkHTV2BMU3ZOAmpdY1Uro0WvG4MNitZro0HpXPhKqVv25rJ3ifP3I1KyYyCPw-AmnI9khaolaC2N-Q9Ug2mUkTqj6oL6OBNF7O0Sw-jiyQqwZx_swf7ywZ59sCBs9iFPvboeOLYjdn9mfgufgddXwJF3Qx_d5AP95WrVgKnLzL27cJiVewgYLfmAk8cuRPTJdnP45yM_AbPTpm8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1350893825</pqid></control><display><type>article</type><title>Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Kang, Hee-Ju ; Kim, Jae-Min ; Stewart, Robert ; Kim, Seon-Young ; Bae, Kyung-Yeol ; Kim, Sung-Wan ; Shin, Il-Seon ; Shin, Myung-Geun ; Yoon, Jin-Sang</creator><creatorcontrib>Kang, Hee-Ju ; Kim, Jae-Min ; Stewart, Robert ; Kim, Seon-Young ; Bae, Kyung-Yeol ; Kim, Sung-Wan ; Shin, Il-Seon ; Shin, Myung-Geun ; Yoon, Jin-Sang</creatorcontrib><description>Childhood adversities have been associated with onset and worse clinical presentations of depression. Epigenetic changes may reflect childhood adversities, while their effects on clinical characteristics of depression are unknown. This study aimed to investigate whether epigenetic changes were associated with childhood adversities, pretreatment characteristics, and treatment outcomes in depressive patients. In 108 patients with major depressive disorders, the methylation status in the promoter of gene encoding serotonin transporter (SLC6A4) was measured. Childhood adversities, socio-demographic and clinical characteristics including assessment scales for depression (Hamilton Depression Rating Scale, HAMD), anxiety (Hamilton Anxiety Rating Scale, HAMA), functioning (Social and Occupational Functioning Assessment Scale, SOFAS), disability (World Health Organization Disability Assessment Schedule-12, WHODAS-12), and quality of life (World Health Organization Quality of Life-Abbreviated form, WHOQOL-BREF) were evaluated at baseline. After a 12-week treatment with antidepressants, the assessment scales were reevaluated. To avoid type I error by multiple comparisons, Bonferroni corrections were applied. Higher SLC6A4 promoter methylation status was significantly associated with childhood adversities, worse clinical presentation (family history of depression, higher perceived stress, and more severe psychopathology assessed by SOFAS, WHODAS-12, and WHOQOL-BREF), but was not associated with treatment outcomes after considering multiple comparisons. SLC6A4 methylation status could be a proxy marker for childhood adversities and a clinical biomarker for certain presentations of depression.
► SLC6A4 methylation was associated with childhood adversity in depressive patients. ► SLC6A4 methylation was associated with more severe depression at presentation. ► Associations of SLC6A4 methylation with treatment outcomes are yet to be determined. ► SLC6A4 methylation could be a biomarker for certain presentations of depression.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/j.pnpbp.2013.01.006</identifier><identifier>PMID: 23333376</identifier><identifier>CODEN: PNPPD7</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Adult ; Adult and adolescent clinical studies ; Aged ; Antidepressive Agents - therapeutic use ; Biological and medical sciences ; Childhood adversity ; Depression ; Depression - drug therapy ; Depression - genetics ; Depression - psychology ; DNA methylation ; DNA Methylation - genetics ; Epigenetics ; Female ; Genetic Association Studies ; Humans ; Life Change Events ; Male ; Medical sciences ; Middle Aged ; Mood disorders ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Serotonin Plasma Membrane Transport Proteins - genetics ; SLC6A4 ; Treatment Outcome</subject><ispartof>Progress in neuro-psychopharmacology & biological psychiatry, 2013-07, Vol.44, p.23-28</ispartof><rights>2013 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-954108fb1315d9af9a09f608894da20e557e673851f598e9e1bc5850351bcc633</citedby><cites>FETCH-LOGICAL-c422t-954108fb1315d9af9a09f608894da20e557e673851f598e9e1bc5850351bcc633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pnpbp.2013.01.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27390874$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23333376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Hee-Ju</creatorcontrib><creatorcontrib>Kim, Jae-Min</creatorcontrib><creatorcontrib>Stewart, Robert</creatorcontrib><creatorcontrib>Kim, Seon-Young</creatorcontrib><creatorcontrib>Bae, Kyung-Yeol</creatorcontrib><creatorcontrib>Kim, Sung-Wan</creatorcontrib><creatorcontrib>Shin, Il-Seon</creatorcontrib><creatorcontrib>Shin, Myung-Geun</creatorcontrib><creatorcontrib>Yoon, Jin-Sang</creatorcontrib><title>Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression</title><title>Progress in neuro-psychopharmacology & biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>Childhood adversities have been associated with onset and worse clinical presentations of depression. Epigenetic changes may reflect childhood adversities, while their effects on clinical characteristics of depression are unknown. This study aimed to investigate whether epigenetic changes were associated with childhood adversities, pretreatment characteristics, and treatment outcomes in depressive patients. In 108 patients with major depressive disorders, the methylation status in the promoter of gene encoding serotonin transporter (SLC6A4) was measured. Childhood adversities, socio-demographic and clinical characteristics including assessment scales for depression (Hamilton Depression Rating Scale, HAMD), anxiety (Hamilton Anxiety Rating Scale, HAMA), functioning (Social and Occupational Functioning Assessment Scale, SOFAS), disability (World Health Organization Disability Assessment Schedule-12, WHODAS-12), and quality of life (World Health Organization Quality of Life-Abbreviated form, WHOQOL-BREF) were evaluated at baseline. After a 12-week treatment with antidepressants, the assessment scales were reevaluated. To avoid type I error by multiple comparisons, Bonferroni corrections were applied. Higher SLC6A4 promoter methylation status was significantly associated with childhood adversities, worse clinical presentation (family history of depression, higher perceived stress, and more severe psychopathology assessed by SOFAS, WHODAS-12, and WHOQOL-BREF), but was not associated with treatment outcomes after considering multiple comparisons. SLC6A4 methylation status could be a proxy marker for childhood adversities and a clinical biomarker for certain presentations of depression.
► SLC6A4 methylation was associated with childhood adversity in depressive patients. ► SLC6A4 methylation was associated with more severe depression at presentation. ► Associations of SLC6A4 methylation with treatment outcomes are yet to be determined. ► SLC6A4 methylation could be a biomarker for certain presentations of depression.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Aged</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Childhood adversity</subject><subject>Depression</subject><subject>Depression - drug therapy</subject><subject>Depression - genetics</subject><subject>Depression - psychology</subject><subject>DNA methylation</subject><subject>DNA Methylation - genetics</subject><subject>Epigenetics</subject><subject>Female</subject><subject>Genetic Association Studies</subject><subject>Humans</subject><subject>Life Change Events</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mood disorders</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Serotonin Plasma Membrane Transport Proteins - genetics</subject><subject>SLC6A4</subject><subject>Treatment Outcome</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU2LFDEQhoMo7rj6CwTJRfCw01aSTnf64GEYXBUGPKjnkE5XMxn6y1RmZf69GWfUm1iXKoqnPnhfxl4KKASI6u2hWKalXQoJQhUgCoDqEVsJU5t1KUX1mK1A5lqbsrphz4gOAJkE9ZTdSHWOulqxdkM0--BSmCc-9_zLblttSj5i2p-GS_dHSHuOLg4n7roHjBTS6Y77vYvOJ4yBUvDE3dTx-Zj8PCLxMPEOl4hEecFz9qR3A-GLa75l3-7ff91-XO8-f_i03ezWvpQyrRtdCjB9K5TQXeP6xkHTV2BMU3ZOAmpdY1Uro0WvG4MNitZro0HpXPhKqVv25rJ3ifP3I1KyYyCPw-AmnI9khaolaC2N-Q9Ug2mUkTqj6oL6OBNF7O0Sw-jiyQqwZx_swf7ywZ59sCBs9iFPvboeOLYjdn9mfgufgddXwJF3Qx_d5AP95WrVgKnLzL27cJiVewgYLfmAk8cuRPTJdnP45yM_AbPTpm8</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>Kang, Hee-Ju</creator><creator>Kim, Jae-Min</creator><creator>Stewart, Robert</creator><creator>Kim, Seon-Young</creator><creator>Bae, Kyung-Yeol</creator><creator>Kim, Sung-Wan</creator><creator>Shin, Il-Seon</creator><creator>Shin, Myung-Geun</creator><creator>Yoon, Jin-Sang</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20130701</creationdate><title>Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression</title><author>Kang, Hee-Ju ; Kim, Jae-Min ; Stewart, Robert ; Kim, Seon-Young ; Bae, Kyung-Yeol ; Kim, Sung-Wan ; Shin, Il-Seon ; Shin, Myung-Geun ; Yoon, Jin-Sang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-954108fb1315d9af9a09f608894da20e557e673851f598e9e1bc5850351bcc633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Aged</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Childhood adversity</topic><topic>Depression</topic><topic>Depression - drug therapy</topic><topic>Depression - genetics</topic><topic>Depression - psychology</topic><topic>DNA methylation</topic><topic>DNA Methylation - genetics</topic><topic>Epigenetics</topic><topic>Female</topic><topic>Genetic Association Studies</topic><topic>Humans</topic><topic>Life Change Events</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mood disorders</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Serotonin Plasma Membrane Transport Proteins - genetics</topic><topic>SLC6A4</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Hee-Ju</creatorcontrib><creatorcontrib>Kim, Jae-Min</creatorcontrib><creatorcontrib>Stewart, Robert</creatorcontrib><creatorcontrib>Kim, Seon-Young</creatorcontrib><creatorcontrib>Bae, Kyung-Yeol</creatorcontrib><creatorcontrib>Kim, Sung-Wan</creatorcontrib><creatorcontrib>Shin, Il-Seon</creatorcontrib><creatorcontrib>Shin, Myung-Geun</creatorcontrib><creatorcontrib>Yoon, Jin-Sang</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Hee-Ju</au><au>Kim, Jae-Min</au><au>Stewart, Robert</au><au>Kim, Seon-Young</au><au>Bae, Kyung-Yeol</au><au>Kim, Sung-Wan</au><au>Shin, Il-Seon</au><au>Shin, Myung-Geun</au><au>Yoon, Jin-Sang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression</atitle><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>2013-07-01</date><risdate>2013</risdate><volume>44</volume><spage>23</spage><epage>28</epage><pages>23-28</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><coden>PNPPD7</coden><abstract>Childhood adversities have been associated with onset and worse clinical presentations of depression. Epigenetic changes may reflect childhood adversities, while their effects on clinical characteristics of depression are unknown. This study aimed to investigate whether epigenetic changes were associated with childhood adversities, pretreatment characteristics, and treatment outcomes in depressive patients. In 108 patients with major depressive disorders, the methylation status in the promoter of gene encoding serotonin transporter (SLC6A4) was measured. Childhood adversities, socio-demographic and clinical characteristics including assessment scales for depression (Hamilton Depression Rating Scale, HAMD), anxiety (Hamilton Anxiety Rating Scale, HAMA), functioning (Social and Occupational Functioning Assessment Scale, SOFAS), disability (World Health Organization Disability Assessment Schedule-12, WHODAS-12), and quality of life (World Health Organization Quality of Life-Abbreviated form, WHOQOL-BREF) were evaluated at baseline. After a 12-week treatment with antidepressants, the assessment scales were reevaluated. To avoid type I error by multiple comparisons, Bonferroni corrections were applied. Higher SLC6A4 promoter methylation status was significantly associated with childhood adversities, worse clinical presentation (family history of depression, higher perceived stress, and more severe psychopathology assessed by SOFAS, WHODAS-12, and WHOQOL-BREF), but was not associated with treatment outcomes after considering multiple comparisons. SLC6A4 methylation status could be a proxy marker for childhood adversities and a clinical biomarker for certain presentations of depression.
► SLC6A4 methylation was associated with childhood adversity in depressive patients. ► SLC6A4 methylation was associated with more severe depression at presentation. ► Associations of SLC6A4 methylation with treatment outcomes are yet to be determined. ► SLC6A4 methylation could be a biomarker for certain presentations of depression.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>23333376</pmid><doi>10.1016/j.pnpbp.2013.01.006</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-5846 |
| ispartof | Progress in neuro-psychopharmacology & biological psychiatry, 2013-07, Vol.44, p.23-28 |
| issn | 0278-5846 1878-4216 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1372055288 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Adult and adolescent clinical studies Aged Antidepressive Agents - therapeutic use Biological and medical sciences Childhood adversity Depression Depression - drug therapy Depression - genetics Depression - psychology DNA methylation DNA Methylation - genetics Epigenetics Female Genetic Association Studies Humans Life Change Events Male Medical sciences Middle Aged Mood disorders Neuropharmacology Pharmacology. Drug treatments Psychiatric Status Rating Scales Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Serotonin Plasma Membrane Transport Proteins - genetics SLC6A4 Treatment Outcome |
| title | Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T14%3A02%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20SLC6A4%20methylation%20with%20early%20adversity,%20characteristics%20and%20outcomes%20in%20depression&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Kang,%20Hee-Ju&rft.date=2013-07-01&rft.volume=44&rft.spage=23&rft.epage=28&rft.pages=23-28&rft.issn=0278-5846&rft.eissn=1878-4216&rft.coden=PNPPD7&rft_id=info:doi/10.1016/j.pnpbp.2013.01.006&rft_dat=%3Cproquest_cross%3E1372055288%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1350893825&rft_id=info:pmid/23333376&rft_els_id=S0278584613000080&rfr_iscdi=true |